Clinical Trial Update: Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Debio 1562 in combination with Rituximab for relapsed/refractory Diffuse Large B-Cell Lymphoma and other B-cell non-Hodgkin lymphomas; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Debio 1562
• Rituximab (rituximab)

Snippet

Sponsor: Debiopharm International SA | Conditions: Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-05-17